Mount Sinai Health System, Emergent BioSolutions, and ImmunoTek Bio Centers Form Collaboration to Develop Emergent’s COVID-19 Hyperimmune Globulin (COVID-HIG) Product Candidate with U.S. Department of Defense Funding

NEXT STORY
Cambridge Security Seals Launches A-MVB™ Line of Tamper-Evident Seals Equipped to Combat the Spread of Viruses and Diseases
PREV STORY
Voltron Therapeutics, Inc. Initiates Animal Testing of Self-Assembling Vaccine in Fight Against COVID-19
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Mount Sinai Health System, Emergent BioSolutions, and ImmunoTek Bio Centers Form Collaboration to Develop Emergent’s COVID-19 Hyperimmune Globulin (COVID-HIG) Product Candidate with U.S. Department of Defense Funding

NEXT STORY
Cambridge Security Seals Launches A-MVB™ Line of Tamper-Evident Seals Equipped to Combat the Spread of Viruses and Diseases
PREV STORY
Voltron Therapeutics, Inc. Initiates Animal Testing of Self-Assembling Vaccine in Fight Against COVID-19
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Immunicum AB (publ) Announces Advancement to a Non-Staggered Inclusion Phase in the Phase Ib/II ILIAD Combination Trial

author_avatar
NASDAQ Market News

Cancer Genetics, Inc. Announces Proposed Public Offering of Common Stock

RUTHERFORD, N.J., Jan. 28, 2019 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a ...

author_avatar
NASDAQ Market News

Calithera Biosciences Highlights Breadth of Innovative Pipeline at R&D Day

-Updated response rate of 50% in advanced renal carcinoma treated with CB-839 + cabozantinib-CB-839 ...

author_avatar
NASDAQ Market News